ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.

Sponsor

Eli Lilly and Company (Industry)

Overall Status

Completed

CT.gov ID

NCT00051506

Collaborator

(none)

Locations

Study Details

Study Description

Brief Summary

The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.

Condition or Disease	Intervention/Treatment	Phase
Lung Neoplasms	Drug: ALIMTA Drug: carboplatin Drug: cisplatin	Phase 2

Study Design

Study Type:

Interventional

Primary Purpose:

Treatment

Outcome Measures

Primary Outcome Measures

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years and Older

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Have a diagnosis of extensive stage small cell lung cancer and can be treated with chemotherapy.
Have received no prior chemotherapy for your disease.
Have at least one measurable lesion.
have an adequate performance status.
Sign an informed consent form.

Exclusion Criteria:

Have previously received chemotherapy for your lung cancer.
Have been treated with a investigational drug within the last 30 days. Have previously completed or withdrawn from this study or any other study investigating ALIMTA.
Have received radiation therapy within the last 1-2 weeks.
Have brain metastasis that is uncontrolled.
Have active infection or other serious condition.

Contacts and Locations

Locations

	Site	City	State	Country
1	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Springdale	Arkansas	United States
2	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Los Angeles	California	United States
3	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Fort Myers	Florida	United States
4	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Miami	Florida	United States
5	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Latham	New York	United States
6	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Burlington	North Carolina	United States
7	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Chapel Hill	North Carolina	United States
8	For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.	Charleston	South Carolina	United States

Sponsors and Collaborators

Eli Lilly and Company

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

Responsible Party:

, ,

ClinicalTrials.gov Identifier:

NCT00051506

Other Study ID Numbers:

7210
H3E-US-JMFW
NCT00062088

First Posted:

Jan 14, 2003

Last Update Posted:

Jul 20, 2006

Last Verified:

Jul 1, 2006

Additional relevant MeSH terms:

Lung Neoplasms

Carboplatin

Study Results

No Results Posted as of Jul 20, 2006